Platelet-rich plasma injections for Peyronie's disease
Official title: Treatment of Peyronie's Disease With Platelet-Rich Plasma: A Randomized, Double-blind, Placebo-controlled Clinical Trial
Run by Herlev Hospital · NCT07117955 · Data updated 2026-11-12
This will test whether injections of a man's own platelet-rich plasma can reduce penile curvature and plaque in men with stable (fibrotic phase) Peyronie's disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 84 (estimated) |
| Sponsor | Herlev Hospital Academic / other |
| Locations | 1 site (Herlev) |
| Status | Recruiting |
| Started | October 21, 2025 |
| Main results expected | June 1, 2028 |
| Study ends | September 1, 2028 |
| Registry record updated | September 22, 2026 |
| Trial ID | NCT07117955 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men aged 18 or older with stable (nonprogressing) Peyronie's disease in the fibrotic phase, a palpable penile plaque, and a curvature between 30° and 95° who can attend in-person visits and have not had prior injectable or surgical PD treatments.
✕Probably not a fit
Patients with active painful or rapidly progressing disease, hourglass or intrapenile deformities, severely calcified plaques that cannot be injected, prior PD injections or surgery, or erectile dysfunction unresponsive to on-demand PDE5 inhibitors are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind trial will enroll 84 men with stable (fibrotic phase) Peyronie's disease and palpable plaque, stratified by baseline curvature (30–60° vs >60°). Participants are randomized 1:1 to receive three weekly intralesional injections of either autologous platelet-rich plasma (PRP) or saline placebo. Outcomes are measured at a 3-month primary follow-up with additional assessments at 6 and 12 months to capture durability of any effect. The protocol includes baseline questionnaires, objective exams, and follow-up visits to compare changes in curvature, plaque characteristics, and related symptoms between groups.
Why it matters
Potential benefit: If successful, PRP injections could offer a minimally invasive option to reduce curvature and improve symptoms for men with stable Peyronie's disease.
How similar studies have gone: Small case series and uncontrolled studies have reported symptomatic improvements with PRP for Peyronie's disease, but high-quality randomized evidence is currently limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Be able to provide written informed consent * Diagnosis of PD without active pain and without progressive curvature over the past 3 months (fibrotic phase). * Penile curvature of 30-95 degrees * Clearly palpable penile plaque Exclusion Criteria: * Erectile Dysfunction unresponsive to on-demand PDE5 inhibitors * Hourglass malformation * Severely calcified plaques where injection is considered unfeasible * Intrapenile plaque * History of priapism. * History of penile fracture. * Previous treatment for PD with injections and/or surgery. * Antithrombotic therapy associated with a high risk of bleeding
Where it's running
-
Herlev and Gentofte University Hospital
Herlev, Denmark Recruiting
Study contacts
- Principal investigator: Mikkel M. Fode, Professor, MD, Ph.d. — Herlev and Gentofte University Hospital
- Study coordinator: Mikael Heering, MD, Ph.d. student
- Email: mikael.heering@regionh.dk
- Phone: +4538688964
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can FAPI or FDG PET/CT help diagnose active Peyronie's disease
This study tests whether FAPI-PET/CT or FDG-PET/CT scans can detect active inflammation or fibroblast activity in men with Peyronie’s disease.
-
Fractional CO2 laser for chronic Peyronie's disease
This will try fractional CO2 laser to reduce plaque-related penile curvature and symptoms in men with chronic, stable Peyronie's disease.
-
Rituximab for treating immune-related side effects from checkpoint inhibitors
This small early-phase trial tests whether a single 100 mg dose of rituximab can help manage immune-related adverse events in adults with malignant melanoma who are on checkpoint inhibitors, alongside a tapering corticosteroid plan.
-
Zinc supplement in acutely hospitalized older adults
In people aged 65 and older who are acutely admitted to the hospital, taking 22 mg of zinc daily for 12 months is tested to see if it lowers inflammatory markers and improves health outcomes.
-
Group-based follow-up for women after obstetric anal sphincter injury
A group-based follow-up program is being tested to see if it can improve quality of life for women who had a tear at the anal sphincter after childbirth.
-
Neoadjuvant immunotherapy for high-risk eye melanoma
This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.